Trial Profile

A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TOL 101 (Primary) ; Antithymocyte globulin; Methylprednisolone; Mycophenolate mofetil; Prednisone; Tacrolimus
Indications Renal transplant rejection
Focus Adverse reactions; First in man
Sponsors Tolera Therapeutics

Most Recent Events

10 Jun 2013 Planned end date changed from Jan 2012 to Jun 2013 as reported by ClinicalTrials.gov.
10 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
07 Sep 2011 Results of dose-escalation phase presented at the 15th Congress of the European Society for Organ Transplantation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com